vs
AXCELIS TECHNOLOGIES INC（ACLS）とNATURES SUNSHINE PRODUCTS INC（NATR）の財務データ比較。上の社名をクリックして会社を切り替えられます
AXCELIS TECHNOLOGIES INCの直近四半期売上が大きい（$238.3M vs $123.8M、NATURES SUNSHINE PRODUCTS INCの約1.9倍）。AXCELIS TECHNOLOGIES INCの純利益率が高く（14.4% vs 3.3%、差は11.1%）。NATURES SUNSHINE PRODUCTS INCの前年同期比売上増加率が高い（4.7% vs -5.6%）。NATURES SUNSHINE PRODUCTS INCの直近四半期フリーキャッシュフローが多い（$7.6M vs $-8.9M）。過去8四半期でNATURES SUNSHINE PRODUCTS INCの売上複合成長率が高い（5.6% vs -2.8%）
Axcelis Technologies Inc.は1995年に設立された米国の半導体製造装置メーカーで、本社はマサチューセッツ州ビバリーにある。世界中の半導体製造業界向けに、半導体生産用基幹設備の設計・製造・保守サービスを展開し、高中電流・高エネルギーイオン注入装置、半導体チップ製造用キュアリングシステムなどを提供している。
Natures Sunshine Products, Inc.（通称NSP）は、ハーブ、ビタミン、ミネラルを含む栄養補助食品やスキンケアなどのパーソナルケア製品の製造を行っています。本社はユタ州リーハイに置き、同州スパニッシュフォークに生産拠点を構えています。
ACLS vs NATR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $238.3M | $123.8M |
| 純利益 | $34.3M | $4.1M |
| 粗利率 | 47.0% | 72.5% |
| 営業利益率 | 15.2% | 4.3% |
| 純利益率 | 14.4% | 3.3% |
| 売上前年比 | -5.6% | 4.7% |
| 純利益前年比 | -31.3% | 1379.4% |
| EPS（希薄化後） | $1.11 | $0.23 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $238.3M | $123.8M | ||
| Q3 25 | $213.6M | $128.3M | ||
| Q2 25 | $194.5M | $114.8M | ||
| Q1 25 | $192.6M | $113.2M | ||
| Q4 24 | $252.4M | $118.2M | ||
| Q3 24 | $256.6M | $114.6M | ||
| Q2 24 | $256.5M | $110.6M | ||
| Q1 24 | $252.4M | $111.0M |
| Q4 25 | $34.3M | $4.1M | ||
| Q3 25 | $26.0M | $5.3M | ||
| Q2 25 | $31.4M | $5.3M | ||
| Q1 25 | $28.6M | $4.7M | ||
| Q4 24 | $50.0M | $-321.0K | ||
| Q3 24 | $48.6M | $4.3M | ||
| Q2 24 | $50.9M | $1.3M | ||
| Q1 24 | $51.6M | $2.3M |
| Q4 25 | 47.0% | 72.5% | ||
| Q3 25 | 41.6% | 73.3% | ||
| Q2 25 | 44.9% | 71.7% | ||
| Q1 25 | 46.1% | 72.1% | ||
| Q4 24 | 46.0% | 72.0% | ||
| Q3 24 | 42.9% | 71.3% | ||
| Q2 24 | 43.8% | 71.4% | ||
| Q1 24 | 46.0% | 71.2% |
| Q4 25 | 15.2% | 4.3% | ||
| Q3 25 | 11.7% | 7.0% | ||
| Q2 25 | 14.9% | 3.7% | ||
| Q1 25 | 15.1% | 5.4% | ||
| Q4 24 | 21.6% | 3.8% | ||
| Q3 24 | 18.3% | 4.6% | ||
| Q2 24 | 20.6% | 5.1% | ||
| Q1 24 | 22.4% | 4.2% |
| Q4 25 | 14.4% | 3.3% | ||
| Q3 25 | 12.2% | 4.2% | ||
| Q2 25 | 16.1% | 4.6% | ||
| Q1 25 | 14.8% | 4.2% | ||
| Q4 24 | 19.8% | -0.3% | ||
| Q3 24 | 18.9% | 3.8% | ||
| Q2 24 | 19.8% | 1.2% | ||
| Q1 24 | 20.4% | 2.1% |
| Q4 25 | $1.11 | $0.23 | ||
| Q3 25 | $0.83 | $0.30 | ||
| Q2 25 | $0.98 | $0.28 | ||
| Q1 25 | $0.88 | $0.25 | ||
| Q4 24 | $1.54 | $-0.02 | ||
| Q3 24 | $1.49 | $0.23 | ||
| Q2 24 | $1.55 | $0.07 | ||
| Q1 24 | $1.57 | $0.12 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $374.3M | $93.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $1.0B | $161.6M |
| 総資産 | $1.4B | $261.1M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $374.3M | $93.9M | ||
| Q3 25 | $449.6M | $95.6M | ||
| Q2 25 | $549.8M | $81.3M | ||
| Q1 25 | $587.1M | $86.5M | ||
| Q4 24 | $571.3M | $84.7M | ||
| Q3 24 | $579.4M | $78.7M | ||
| Q2 24 | $548.3M | $68.7M | ||
| Q1 24 | $530.2M | $77.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $1.0B | $161.6M | ||
| Q3 25 | $1.0B | $166.7M | ||
| Q2 25 | $1.0B | $163.7M | ||
| Q1 25 | $1.0B | $167.1M | ||
| Q4 24 | $1.0B | $161.0M | ||
| Q3 24 | $975.6M | $162.6M | ||
| Q2 24 | $934.9M | $156.4M | ||
| Q1 24 | $901.7M | $159.7M |
| Q4 25 | $1.4B | $261.1M | ||
| Q3 25 | $1.4B | $264.8M | ||
| Q2 25 | $1.3B | $254.9M | ||
| Q1 25 | $1.3B | $252.7M | ||
| Q4 24 | $1.3B | $240.9M | ||
| Q3 24 | $1.3B | $245.3M | ||
| Q2 24 | $1.3B | $235.8M | ||
| Q1 24 | $1.3B | $247.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $-6.6M | $9.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $-8.9M | $7.6M |
| FCFマージンFCF / 売上 | -3.7% | 6.1% |
| 設備投資強度設備投資 / 売上 | 1.0% | 1.9% |
| キャッシュ転換率営業CF / 純利益 | -0.19× | 2.41× |
| 直近12ヶ月FCF直近4四半期 | $107.0M | $28.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $-6.6M | $9.9M | ||
| Q3 25 | $45.4M | $18.5M | ||
| Q2 25 | $39.7M | $4.3M | ||
| Q1 25 | $39.8M | $2.6M | ||
| Q4 24 | $12.8M | $12.2M | ||
| Q3 24 | $45.7M | $9.6M | ||
| Q2 24 | $40.1M | $1.3M | ||
| Q1 24 | $42.2M | $2.2M |
| Q4 25 | $-8.9M | $7.6M | ||
| Q3 25 | $43.3M | $16.8M | ||
| Q2 25 | $37.7M | $3.0M | ||
| Q1 25 | $34.8M | $1.5M | ||
| Q4 24 | $8.1M | $10.0M | ||
| Q3 24 | $41.8M | $7.9M | ||
| Q2 24 | $38.1M | $-2.0M | ||
| Q1 24 | $40.6M | $-1.5M |
| Q4 25 | -3.7% | 6.1% | ||
| Q3 25 | 20.3% | 13.1% | ||
| Q2 25 | 19.4% | 2.6% | ||
| Q1 25 | 18.1% | 1.3% | ||
| Q4 24 | 3.2% | 8.5% | ||
| Q3 24 | 16.3% | 6.9% | ||
| Q2 24 | 14.8% | -1.9% | ||
| Q1 24 | 16.1% | -1.4% |
| Q4 25 | 1.0% | 1.9% | ||
| Q3 25 | 0.9% | 1.3% | ||
| Q2 25 | 1.0% | 1.2% | ||
| Q1 25 | 2.6% | 1.0% | ||
| Q4 24 | 1.8% | 1.9% | ||
| Q3 24 | 1.5% | 1.5% | ||
| Q2 24 | 0.8% | 3.0% | ||
| Q1 24 | 0.6% | 3.3% |
| Q4 25 | -0.19× | 2.41× | ||
| Q3 25 | 1.75× | 3.46× | ||
| Q2 25 | 1.27× | 0.81× | ||
| Q1 25 | 1.39× | 0.55× | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.94× | 2.21× | ||
| Q2 24 | 0.79× | 0.97× | ||
| Q1 24 | 0.82× | 0.94× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ACLS
| Products | $224.6M | 94% |
| Services | $13.7M | 6% |
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
